Showing results (31-40 of 72) with videos related to
Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|February 6, 2019
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinomaSandra P D'Angelo, Matthias Hunger, Andrew S Brohl, et al.Journal of Neuro-Oncology|June 18, 2018
Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastasesTyler P Robin, Robert E Breeze, Derek E Smith, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2013
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumorsAntonio Jimeno, Glen J Weiss, Wilson H Miller, et al.Future Oncology (London, England)|July 29, 2024
Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trialAlexander J Stratigos, Chieh-I Chen, Cristina Ivanescu, et al.JAMA Oncology|November 23, 2022
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical TrialJoseph M Unger, Amy Darke, Megan Othus, et al.Cancers|July 26, 2020
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 ImmunotherapyCarol M Amato, Jennifer D Hintzsche, Keith Wells, et al.Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.Journal for Immunotherapy of Cancer|May 17, 2020
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trialSandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, et al.Cancer|January 23, 2024
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancersAlain P Algazi, James Moon, Christopher D Lao, et al.The Lancet. Oncology|September 6, 2016
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialHoward L Kaufman, Jeffery Russell, Omid Hamid, et al.Pageof 8